Pilot Trial of Adjuvant Paclitaxel Plus Estramustine in Resected High-Risk Prostate Cancer

Urology

Volumn 71, Issue 5, 2008, Pages 942-946

  Cetnar, Jeremy P ^a   Malkowicz, S Bruce ^b   Palmer, Steven C ^b   Wein, Alan J ^b   Vaughn, David J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRAMUSTINE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; WARFARIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; FATIGUE; FEASIBILITY STUDY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL TOXICITY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TIME SERIES ANALYSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; ESTRAMUSTINE; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PILOT PROJECTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 42749086530     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.11.117     Document Type: Article

References (21)

1. American Cancer Society: Cancer facts and figures, 2007. http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf Accessed September 5, 2007
2. Kattan M.W., Wheeler T.M., and Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17 (1999) 1499-1507
3. Graefen M., Karakiewicz P.I., Cagiannos I., et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 20 (2002) 951-956
4. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
5. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
6. D'Amico A.V., Whittington R., Malkowicz B.S., et al. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol 160 (1998) 2096-2101
7. Vaughn D.J., Brown A.W., Harker W.G., et al. Multicenter phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen independent prostate carcinoma. Cancer 100 (2004) 746-750
8. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329
9. Bolla M., van Poppel H., Collette L., et al. Posteoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572
10. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781
11. Issacs J.T., Heston W.D.W., Weissman R.M., et al. Animal models of the hormone-sensitive and insensitive prostatic adenocarcinomas. Cancer Res 38 (1978) 4353-4359
12. Schmidt J.D., Gibbons R.P., Murphy G.P., et al. Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation. Eur Urol 29 (1996) 425-433
13. Pilepich M.W., Al-Sarraf M., Rotman M., et al. Adjuvant chemotherapy with adriamycin, cytoxan, and cis-platinum in high-grade carcinoma of the prostate treated with definitive radiotherapy (RTOG pilot 81-12). Am J Clin Oncol 9 (1986) 135-138
14. Wang J., Halford S., Rigg R., et al. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 86 (2000) 675-680
15. Kibel A.S., Rosenbaum E., Kattan M.W., et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 177 (2007) 1777-1781
16. Carter G.E., Lieskovsky G., Skinner D.G., et al. Results of local and/or systemic adjuvant therapy in the management of pathologic stage C or D1 prostate cancer following radical prostatectomy. J Urol 142 (1989) 1266-1270
17. Bagley Jr. C.M., Lane R.F., Blasko J.C., et al. Adjuvant chemohormonal therapy of high risk prostate carcinoma: ten year results. Cancer 94 (2002) 2728-2732
18. White R.V., Babayan R.K., and Krikarian J. Adjuvant chemotherapy for stage D1 adenocarcinoma. Urology 21 (1983) 270-272
19. Kreis W., Budman D., and Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Prostate 9 (1986) 387-395
20. Van Poppel H., Werbrouck P.W., Baert L., et al. Effect of estramustine phosphate on free androgens: a comparison study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostate cancer. Acta Urol Belg 58 (1990) 89-95
21. Fizazi K., Hudes G., and Berry K. Does adding estramustine to chemotherapy improve survival in patients with castration-refractory prostate cancer?. Results from a meta-analysis on individual data of randomized trials assessing chemotherapy with and without estramustine. Proceedings from the American Society of Clinical Oncology; June 1-5 (2007) Abstract 226, Chicago, IL